Companies Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals (SYRS): executive pay, fiscal 2023
Free brief. Every figure links to the company’s own filing.
Syros Pharmaceuticals, Inc. no longer files a proxy statement; its last pay data is FY2023.
CEO pay, last three years
- $1,041,697FY2023
CEO total pay was $1,041,697 in fiscal 2023; the brief holds no earlier figure for this CEO.
FY2023: salary $479,092 · bonus $0 · stock awards $369,460 · option awards $0
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nancy Simonian | $635,385 | $0 | $477,174 | $0 | $318,986 | $0 | $5,237 | $1,436,782 |
| Former President & Chief Executive Officer | ||||||||
| Conley Chee | 479,092 | 0 | 369,460 | 0 | 192,455 | 0 | 690 | 1,041,697 |
| President & Chief Executive Officer | ||||||||
| Eric Olson | 409,791 | 0 | 140,700 | 0 | 0 | 0 | 385,277 | 935,768 |
| Former Chief Scientific Officer | ||||||||
| David Roth | 516,154 | 0 | 160,800 | 0 | 197,600 | 0 | 1,980 | 876,534 |
| Chief Medical Officer | ||||||||
| Jason Haas | 485,185 | 0 | 160,800 | 0 | 185,744 | 0 | 1,290 | 833,019 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Nancy Simonian | $1,436,782 | $3,487,880 | — | ↓ −2,051,098 |
| Conley Chee | 1,041,697 | — | — | — |
| Eric Olson | 935,768 | 1,668,669 | — | ↓ −732,901 |
| David Roth | 876,534 | 1,759,093 | — | ↓ −882,559 |
| Jason Haas | 833,019 | 1,416,010 | — | ↓ −582,991 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company aims to reward value creation for stockholders and attract, motivate, and retain executive officers by aligning their interests with those of stockholders through a mix of short-term and long-term performance-based incentives. The compensation committee considers market comparables, individual and corporate performance, and the desire to foster long-term commitment while managing dilution.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2023
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Conley Chee | PSU | 2023-02-16 | — | 35,000 | — | — | $369,460 |
| Conley Chee | RSU | 2023-02-16 | — | — | 35,000 | — | — |
| Conley Chee | RSU | 2023-12-02 | — | — | 86,000 | — | — |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Conley Chee | $0 | $369,460 | $0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Roth | Option | 396 | 75.4 | — |
| Eric Olson | Option | 453 | 13.88 | — |
| Eric Olson | Option | 2,584 | 30.4 | — |
| David Roth | Option | 3,471 | 114.1 | — |
| Eric Olson | Option | 3,477 | 30.38 | — |
| Eric Olson | Option | 3,955 | 15.9 | — |
| Conley Chee | Option | 5,420 | 15.9 | — |
| Conley Chee | RSU | 6,000 | — | 46,740 |
| David Roth | RSU | 6,000 | — | 46,740 |
| Jason Haas | RSU | 6,000 | — | 46,740 |
| Eric Olson | Option | 6,069 | 114.1 | — |
| Eric Olson | Option | 6,349 | 109 | — |
| David Roth | Option | 6,775 | 15.9 | — |
| Jason Haas | Option | 6,775 | 15.9 | — |
| Eric Olson | Option | 7,499 | 67.1 | — |
| Eric Olson | Option | 7,499 | 109 | — |
| Eric Olson | Option | 8,415 | 75.4 | — |
| Conley Chee | Option | 15,752 | 48.1 | — |
| Conley Chee | RSU | 17,000 | — | 132,430 |
| Nancy Simonian | RSU | 18,000 | — | 140,220 |
| David Roth | RSU | 18,875 | — | 147,036 |
| Jason Haas | RSU | 18,875 | — | 147,036 |
| David Roth | RSU | 20,000 | — | 155,800 |
| Nancy Simonian | Option | 20,314 | 15.9 | — |
| Conley Chee | Option | 22,250 | 6.73 | — |
| David Roth | Option | 24,875 | 6.73 | — |
| Jason Haas | Option | 24,875 | 6.73 | — |
| Jason Haas | Option | 34,382 | 45.4 | — |
| Conley Chee | RSU | 35,000 | — | 272,650 |
| Conley Chee | PSU | 35,000 | — | 272,650 |
| David Roth | RSU | 40,000 | — | 311,600 |
| David Roth | PSU | 40,000 | — | 311,600 |
| Jason Haas | RSU | 40,000 | — | 311,600 |
| Jason Haas | PSU | 40,000 | — | 311,600 |
| Nancy Simonian | RSU | 40,000 | — | 311,600 |
| Nancy Simonian | RSU | 40,125 | — | 312,574 |
| Nancy Simonian | Option | 57,500 | 6.73 | — |
| Conley Chee | RSU | 86,000 | — | 669,940 |
| Conley Chee | PSU | 86,000 | — | 669,940 |
| Nancy Simonian | RSU | 118,700 | — | 924,673 |
| Nancy Simonian | PSU | 118,700 | — | 924,673 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Peter WirthIndependent | $80,000 | $14,800 | $15,604 | — | $0 | $110,404 |
| Marsha H. FanucciIndependent | 54,375 | 14,800 | 15,604 | — | 0 | 84,779 |
| S. Gail EckhardtIndependent | 52,000 | 14,800 | 15,604 | — | 0 | 82,404 |
| Richard A. YoungIndependent | 51,750 | 14,800 | 15,604 | — | 0 | 82,154 |
| Deborah DunsireIndependent | 48,670 | 14,800 | 15,604 | — | 0 | 79,074 |
| Andrew M. OhIndependent | 48,125 | 14,800 | 15,604 | — | 0 | 78,154 |
| Timothy C. TysonIndependent | 45,625 | 14,800 | 15,604 | — | 0 | 76,029 |
| Mark J. AllesIndependent | 35,625 | 14,800 | 15,604 | — | 0 | 66,029 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $416,170 |
| Equity awards (grant-date value) | $118,400 |
| All other compensation | $0 |
| Total cost of the board | $534,570 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Syros Pharmaceuticals as a peer
Companies that benchmark against SYRS
3 companies name SYRS as a compensation peer
- Adverum Biotechnologies, Inc.ADVMFY2024
- SELLAS Life Sciences Group, Inc.SLSFY2025
- Verastem, Inc.VSTMFY2025
Each company listed discloses SYRS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SYRS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Syros Pharmaceuticals, Inc. | 2023 | Conley Chee | $479,092 | $369,460 | $0 | $192,455 | $1,041,697 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (20 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Nancy Simonian. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 1,436,782. View filing ↗
- Section 01, Conley Chee. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 1,041,697. View filing ↗
- Section 01, Eric Olson. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 935,768. View filing ↗
- Section 01, David Roth. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 876,534. View filing ↗
- Section 01, Jason Haas. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 833,019. View filing ↗
- Section 03, Conley Chee PSU. 10-K, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Conley Chee RSU. 10-K, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Conley Chee RSU. 10-K, filed 2024-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Peter Wirth. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 110,404. View filing ↗
- Section 08, Marsha H. Fanucci. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 84,779. View filing ↗
- Section 08, S. Gail Eckhardt. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 82,404. View filing ↗
- Section 08, Richard A. Young. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 82,154. View filing ↗
- Section 08, Deborah Dunsire. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 79,074. View filing ↗
- Section 08, Andrew M. Oh. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 78,154. View filing ↗
- Section 08, Timothy C. Tyson. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 76,029. View filing ↗
- Section 08, Mark J. Alles. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 66,029. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 416,170 + equity 118,400 + all other 0 = 534,570, summed across the director compensation table rows.
- Syros Pharmaceuticals, Inc. (subject), Section 10b CEO total. 10-K, filed 2024-04-23. CEO total compensation as printed in Syros Pharmaceuticals, Inc.'s own proxy. As printed: 1,041,697. View filing ↗